The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
about
Diagnosis and management of psoriatic arthropathy in primary care.Psoriatic arthritis: Epidemiology, diagnosis, and treatment.Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience.A discrete choice experiment to explore patients' willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis.Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety.Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis.Ustekinumab: a review of its use in psoriatic arthritis.Advances in the management of psoriatic arthritis.Apremilast: A Review in Psoriasis and Psoriatic Arthritis.Points to Consider in the Foundation of Multidisciplinary Units for Psoriatic Arthritis: A Delphi Study and a Systematic Review of the Literature.BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics.Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control.Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature.Tuberculosis and biologics in rheumatology: India - A special situation.British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016.Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.Risk of tuberculosis comparison in new users of antitumour necrosis factor-α and with existing disease-modifying antirheumatic drug therapy.Ustekinumab for the treatment of psoriatic arthritis.Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases.Psoriatic arthritis.Outcome measures of disease activity in inflammatory arthritis.Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review.Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK.Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies.Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
P2860
Q33951693-22956137-1B9E-4351-91A3-1FE6111D194AQ34047760-AC689C5A-8E7E-467D-BC8C-0F18B9CD1E87Q36404862-5E9C9625-128A-421D-BB88-9167D4ADC5D0Q37308871-169BE255-B7B3-4E02-A6B4-6EA3252D0CC8Q37427411-50D6F772-27F3-4C8B-94E9-54D0A981FC37Q37453027-F6CA8775-CB87-426C-9F00-C11FD9AA2C5AQ38204241-510E9D6F-2A93-4DC7-A149-A60C7571BED8Q38219589-EB6615F0-1828-4954-86EF-54827E024246Q38219591-D8A22C59-774D-48AF-A1DB-E4FCDC208996Q38227264-4AFDBB57-E81D-47DB-B56B-B13797857E18Q38556637-7540790C-E429-4B17-A4AA-69E28F73B213Q38809161-EA877968-25BE-41A9-BD80-9F36DECAE7CFQ38936634-2BE22D6D-D62C-4FAD-AF43-EBEF37DFB6E7Q38941723-646FDFDC-4B22-4A76-978F-DF4DFC72105AQ38978414-0399A5DD-63DC-494F-8FAD-B62CEBD9F04DQ39449936-C291C302-A592-440C-838C-7C8489DDBBF6Q40590985-29DBD2B1-03C2-48E9-8667-D4A09E73DEC9Q46129663-441C3834-B892-4DA7-AA1B-3AC0AB516831Q47688424-D227D049-83C9-42DE-98C9-5B7193448077Q47717769-8860FBF2-EF44-43A6-A604-865BA89AE7DBQ48086737-7C91D06A-102B-4060-8736-30581E349D5CQ50115818-6AB868E6-32CB-4DA0-9D0C-2E6BD4E21F45Q51656945-574B8BC7-DD35-4246-9F29-1ACF5DD3FA28Q52549412-CED94954-E683-411C-8B7C-57F3F633E690Q55109332-E22E6E23-99A6-47B7-A250-BA73CDEC8607Q55452701-5CA40A43-A085-42B8-A7B0-89B77B959F57Q55690278-9864E51C-92BA-464A-9025-B56C53960D0EQ57169747-B0151E36-19AB-4880-82D3-ED2F7C7F96BC
P2860
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
@en
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
@en-gb
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
@nl
type
label
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
@en
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
@en-gb
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
@nl
prefLabel
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
@en
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
@en-gb
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
@nl
P2093
P50
P356
P1433
P1476
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
@en
P2093
Anthony Ormerod
BSR Clinical Affairs Committee ...... nes Working Group and the BHPR
David Chandler
Eleanor Korendowych
Neil J McHugh
Nicola Waldron
Stuart Kyle
Susan Oliver
P2860
P304
P356
10.1093/RHEUMATOLOGY/KET187
P50
P577
2013-07-25T00:00:00Z